Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct-Nov;30(7-8):1833-1841.
doi: 10.1080/09273948.2021.1962916. Epub 2021 Aug 11.

Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy

Fabrizio Gozzi  1 , Raffaella Aldigeri  2 , Valentina Mastrofilippo  1 , Luca De Simone  1 , Elena Bolletta  1 , Jacopo Marzano  3 , Danilo Iannetta  4 , Marco Coassin  5 , Fiorella Ilariucci  6 , Angela Ferrari  6 , Stefano Luminari  6   7 , Francesco Merli  6 , Stefania Croci  8 , Alessandro Zerbini  8 , Enrico Farnetti  9 , Davide Nicoli  9 , Riccardo Valli  10 , Ione Tamagnini  10 , Alberto Cavazza  10 , Carlo Salvarani  7   11 , Luigi Fontana  4 , Luca Cimino  1
Affiliations
Free article

Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy

Fabrizio Gozzi et al. Ocul Immunol Inflamm. 2022 Oct-Nov.
Free article

Abstract

Purpose: To investigate the role of combined systemic and local chemotherapy in improving the survival of patients with vitreoretinal lymphoma (VRL).

Methods: Patients with VRL consecutively seen from 2006 to 2020 were retrospectively reviewed; data on the presence and time of central nervous system (CNS) involvement and treatment regimen (systemic, local or combined chemotherapy) were collected. Overall survival (OS) and progression-free survival (PFS) were calculated for each group.

Results: Forty-three eyes of 22 subjects with histology-proven VRL were included. Mean time of survival was 64.8 months (SE±10.8). Twelve patients (57%) presented CNS involvement, which was significantly associated with progression (r = 0.48, P = .03) and death (r = 0.56, P = .009). The isolated primary VRL group had a 5-year OS of 80%. Combined systemic and local chemotherapy reduced the risk of death by 82% (hazard ratio 0.18[0.04- 0.85]) in the entire cohort.

Conclusion: Combined systemic and local chemotherapy significantly improved OS but not PFS of patients affected by VRL.

Keywords: CNS involvement; Vitreoretinal lymphoma; chemotherapy; survival; uveitis masquerade syndrome.

PubMed Disclaimer